Drugs Licensing Packaging Pharma Companies 
World of DTC Marketing
APRIL 12, 2021
QUICK READ: Pharma supply chain issues are a concern for us all but especially patients. The goal of getting a drug to market as fast as possible so they can recoup drug development costs has the potential for mistakes that could cost lives. We can’t continue to develop drugs the same way as we have done before.
pharmaphorum
OCTOBER 7, 2021
The factory will be able to supply up to 500 million doses of mRNA shots a year, and cover the full spectrum of manufacturing from drug substance production through to full/finish and packaging, according to the company.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JUNE 11, 2021
The Philadelphia-based company said it had taken the decision to go down the biologics license application (BLA) route for Covaxin based on FDA feedback to the EUA data package it had submitted to the agency. Bharat has also reported data suggesting the shot is effective against the beta (B.1.351) 1.351) variant.
pharmaphorum
MAY 27, 2022
However, if considered early in the drug development plan, compliance is by no means insurmountable and would be offset by the benefits of digital healthcare tools for patient engagement. There is a huge opportunity for pharma companies to capitalise on by focusing on increased DEI in clinical trials. What comes next?
Advarra
JULY 19, 2022
If the sponsor wants their drug approved, they need to complete all clinical studies and submit an application. Q: Please discuss the transfer of investigational new drug (IND) sponsorship from one sponsor to another and that process. The sponsor is the pharmaceutical company conducting the trial. A: No, this is not allowed.
Drug Discovery World
MARCH 29, 2023
Politico published a summary of the key propositions outlined in the draft 2 , and DDW’s Multimedia Editor Megan Thomas investigates their intention, and observes how the industry has responded. Key proposals Approved drugs must launch in all EU countries within two years Politico described this as a measure to ensure a level playing field.
pharmaphorum
AUGUST 25, 2021
Jirair Ratevosian, executive director of global patient solutions and government affairs at Gilead Sciences, tells us how his company utilised previously developed partnerships and their knowledge of providing global access to HIV treatments to distribute Remdesivir. We went back to what we do best … we engaged our network of companies.
Expert insights. Personalized for you.
187 
Let's personalize your content